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Abstract
Objective. Selective IgA deficiency (sIgAD) is the most common
primary immunodeficiency in Western countries. Patients can
suffer from recurrent infections and autoimmune diseases because
of a largely unknown aetiology. To increase insights into the
pathophysiology of the disease, we studied memory B and T cells
and cytokine concentrations in peripheral blood. Methods. We
analysed 30 sIgAD patients (12 children, 18 adults) through
detailed phenotyping of peripheral B-cell, CD8+ T-cell and CD4+ T-
cell subsets, sequence analysis of IGA and IGG transcripts, in vitro
B-cell activation and blood cytokine measurements. Results. All
patients had significantly decreased numbers of T-cell-dependent
(TD; CD27+) and T-cell-independent (TI; CD27) IgA memory B cells
and increased CD21low B-cell numbers. IgM+IgD memory B cells
were decreased in children and normal in adult patients. IGA and
IGG transcripts contained normal SHM levels. In sIgAD children,
IGA transcripts more frequently used IGA2 than controls (58.5% vs.
25.1%), but not in adult patients. B-cell activation after in vitro
stimulation was normal. However, adult sIgAD patients exhibited
increased blood levels of TGF-b1, BAFF and APRIL, whereas they
had decreased Th1 and Th17 cell numbers. Conclusion. Impaired
IgA memory formation in sIgAD patients is not due to a B-cell
activation defect. Instead, decreased Th1 and Th17 cell numbers
and high blood levels of BAFF, APRIL and TGF-b1 might reflect
disturbed regulation of IgA responses in vivo.These insights into
B-cell extrinsic immune defects suggest the need for a broader
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immunological focus on genomics and functional analyses to
unravel the pathogenesis of sIgAD.
Keywords: B-cell memory, cytokine concentration, IgA, selective
IgA deficiency, Th1 cells, Th17 cells
INTRODUCTION
Selective IgA deficiency (sIgAD), the most common
primary immunodeficiency in Western countries, is
defined by very low to absent serum levels of IgA
with normal IgG and IgM.1 The prevalence differs
between countries and ranges between 1:328 and
1:3040.2 The majority of the individuals with
absent serum IgA are asymptomatic and identified
by coincidental findings.3 Still, a number of
patients are prone to suffer from recurrent
infections and to develop autoimmune diseases
and/or allergies.3 Altogether, the clinical
symptoms of immunodeficiency and immune
dysregulation are much higher in sIgAD than in
the normal population. This concerns
autoimmunity with a prevalence of 25–31% and
includes systemic lupus erythematosus,
rheumatoid arthritis and type 1 diabetes.4,5 In
addition, between 18% and 56% of sIgAD
patients suffer from one or more allergies.4 The
pathogenesis of the disease is unknown.
We and others have shown that IgA memory B
cells can derive from T-cell-dependent (TD) and T-
cell-independent (TI) responses (Figure 1a).6,7 In
human peripheral blood, most IgA memory B cells
express CD27 and originate from CD40L-mediated
T-cell help in germinal centres. In contrast, CD27-
negative IgA memory B cells originate from TI
responses in the intestinal tract and are
characterised by high IgA2 usage and increased
reactivity to intestinal bacteria.8 This CD40L-
independent pathway involves the binding of the
cytokine A proliferation-inducing ligand (APRIL)
to its receptor transmembrane activator and
CAML interactor (TACI), resulting in the
expression of activation-induced cytidine
deaminase (AID).7,9 Additional cytokines, such as
transforming growth factor-beta (TGF-b),
vasoactive intestinal peptide (VIP) and IL-10,
induce germline IGA transcripts leading to IGA
class switching.7,10,11 Previous studies described
reduced numbers of Ig class-switched memory B
cells and CD19+IgA+ B cells in sIgAD patients.12-14
Recently, Blanco et al. grouped sIgAD and other
antibody deficiency patients based on the
phenotyping of their B-cell compartment. They
proposed that sIgAD patients could segregate into
two groups based on differences in IgA+ memory
B-cell numbers.15 However, the authors did not
discriminate between CD27+ and CD27 IgA+
memory B cells. The analysis of the T-cell
compartment in sIgAD patients has shown that
CD4+ T cells were reduced.12 T-helper cells in
sIgAd have only been studied after in vitro
stimulation and data on cell counts are lacking.14
Several studies have addressed the issue of
genetic defects in the pathogenesis of sIgAD. In
some patients, chromosome 18p deletions or
mutations in TNFRSF13B, the gene encoding TACI,
have been found.16-18 However, these genetic
variants might be disease-modifying rather than
disease-causing. Furthermore, distinct HLA
haplotypes seem to confer risk for the
development of sIgAD.19,20 More recently,
Bronson et al.21 performed a genome-wide
association study (GWAS) meta-analysis of 1635
patients with IgAD and 4852 controls and found
that the PVT1, ATG13–AMBRA1, AHI1 and
CLEC16A genes were significantly associated with
sIgAD. Therefore, cytogenetic abnormalities, HLA
haplotype associations and known monogenetic
disorders are likely involved in the aetiology of
sIgAD.22
Previously, Wang et al.23 proposed that the lack
of serum IgA results from the absence of IGA class
switching in B cells in sIgAD patients. They
observed that unstimulated peripheral blood
mononuclear cells (PBMC) from patients had
fewer Ca germline transcripts and Sl-Sa fragments
than control subjects.24,25 However, whether these
Ca transcripts are different in somatic
hypermutation (SHM) levels or there is
preferential class switching towards either IGA1 or
IGA2 in these patients is currently unknown. It
would be noteworthy to solve this in order to
gain insight into the potential genetic defects
involved in molecular maturation of IgA+ B cells.
To study underlying B-cell intrinsic and extrinsic
defects in sIgAD, we performed
immunophenotyping of the B-cell, CD8 T-cell and
CD4 T-cell compartments, as well as genetic
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analysis of IGA transcripts in children and adults
with sIgAD. We also measured cytokine
concentrations in blood samples of adult IgAD
patients.
Here, we show that both TD- and TI-derived IgA
memory B cells are reduced or absent in sIgAD
patients. Interestingly, molecular maturation and
B-cell activation were not impaired, but Th1 and
Th17 numbers were decreased in adult sIgAD
patients. In contrast, we observed increased
cytokine concentrations in B-cell activating factor
(BAFF), APRIL and TGF-b1. Together, these results
show that SIgAD patients do not exhibit class
switch abnormalities, but a defect in the
formation of IgA memory B cells, and Th1 and
Th17 cells.
RESULTS
We included 30 sIgAD patients (12 children, 18
adults) with IgA serum concentrations
< 0.07 g L1 (patient details in Supplementary
table 1). To obtain more insights into the
pathogenesis of sIgAD that might be useful to
develop potential treatment strategies, we
included mainly symptomatic patients. Twenty-six
out of 30 patients suffered from recurrent
respiratory tract infections, 11/25 patients
experienced one or more allergies, and 5/27
patients had autoimmune complications. Two
adult patients carried heterozygous mutations in
TNFRSF13B.
Decreased CD27 and CD27+ IgA+ memory B
cells in sIgAD patients
To investigate whether IgA memory B-cell
formation was affected, we analysed peripheral
blood B cells in patients (children n = 11, adults
n = 14) and compared them with healthy controls
(children n = 67, adults n = 29; Figure 1a).26,27 We
found that both children and adult patients
exhibited decreased IgA memory B cells
(Figure 1b). Furthermore, IgA memory B cells were
undetectable in 11 out of 14 adult patients. In
children with sIgAD, we found increased numbers
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Figure 1. Reductions in CD27+ and CD27 IgA+ memory B cells in sIgAD patients. (a) Schematics of TI and TD IgA responses. (b) Quantification
of CD27 and CD27+ IgA+ memory B cells. Adult controls n = 29, sIgAD patients n = 14; paediatric controls n = 67, sIgAD patients n = 10. (c)
Quantification of B-cell subsets in children and (d) adults. The number of patients are indicated in the upper right corner for B-cell subsets,
except for IgG+ memory B cells (n = 11). b–d, red lines indicate median values. Statistics were calculated with the Mann–Whitney U-test;
***P < 0.001, ****P < 0.0001. Technical replicates were not performed. Numbers depict biological replicates.
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of naive and CD21low B cells, but low IgM+IgD
memory B-cell numbers (Figure 1c). In contrast, in
adult patients, only CD21low B cells were
increased. IgG memory B cells were studied only
in adults, and these were similar to controls
(Figure 1d).
Interestingly, some of these abnormalities in
peripheral blood B cells of sIgAD patients showed
similarities with B-cell abnormalities observed in
CVID patients, such as reduced memory B cells
and increased numbers of CD21low B cells.28 Still,
CVID patients are low in serum IgG, and the
different subgroups (as described previously by
Driessen et al.26) showed additional defects in
naive and memory B-cell subsets that we did not
observe in sIgAD patients (Supplementary figure
2). Thus, sIgAD patients showed signs of chronic
inflammation as observed by increased CD21low B
cells, and these were explicitly defective in IgA B-
cell memory.
Ig class switching and SHM in transcripts of
sIgAD patients
Similar to others,24 we detected low numbers of
rearranged IGA transcripts in PBMCs of patients
with sIgAD. We analysed unique sequences to
determine Ig subclasses and compared their
relative distribution to sequence analysis in
controls. IGA transcripts from paediatric patients
consisted of IGA2 significantly more often (58.5%)
than controls (25.1%) (Figure 2b), whereas in
adult patients, IGA2 transcripts were used less
frequently (18.1%) than in controls (50%;
Figure 2b). Despite B cells of adult sIgAD patients
having reduced usage of IGA2, distal IGG2
subclass usage was normal (Supplementary figure
3a).
Somatic hypermutation (SHM) frequencies in
IGHV regions in IGA transcripts from patients
were analysed. We observed that these were
similar to controls (Figure 1c). Moreover, we did
not observe differences in the selection for
replacement mutations in the complementarity
determining regions (CDR) (Figure 1d). Likewise,
SHM frequencies and selection for replacement
mutations in IGHV of adult patients’ IGG
transcripts were similar to controls
(Supplementary figure 3b and c). Thus, the
reduction in IGA2 usage in sIgAD adults is not due
to a general defect in SHM or class switch
recombination, but rather a selective defect in IgA
responses and memory B-cell formation.
Normal B-cell activation of adult sIgAD
patients’ naive B cells
B cells from sIgAD patients have previously been
shown to produce IgA following in vitro
stimulation with CD40L and IL-21.29 However, it is
currently unknown whether sIgAD patients show
differences in B-cell activation after short-term
stimulation with TD or TI stimuli. To investigate
this, we stimulated peripheral blood B cells from
adult patients (patient numbers: 14, 22 and 25)
with several TD (anti-CD40) and TI (anti-IgM, CpG
or APRIL plus TGF-b) stimuli for 48 h. Cultures
with either stimulus resulted in the upregulation
of CD80, CD86, CD69 and CD95 on peripheral
blood B cells of adult patients and controls
(Figure 3). Thus, in symptomatic sIgAD adults, B-
cell activation did not appear to be defective
upon stimulation with TD or TI stimuli.
Reduced Th1 and Th17 cell numbers and
increased serum TGF-b1, APRIL and BAFF
levels
To address a potential B-cell extrinsic defect in
sIgAD, we phenotyped CD4+ and CD8+ T-cell
subsets and measured peripheral blood
concentrations of several cytokines implicated in
IgA class switching: TGF-b1, APRIL and BAFF.11,30
We found that IgA-deficient children had higher
numbers of total CD8+ T cells, naive CD4+ and
CD8+ T cells, as well as CD4+ central memory T
cells than controls (Supplementary figure 4a). In
sIgAD adults, naive CD4+ and CD8+, memory CD4+,
Th2, follicular helper (Tfh) and regulatory (Treg)
cell numbers were similar to controls. In contrast,
we observed higher numbers of CD8+ central
memory T cells (Figure 4b) and lower numbers of
Th1 and Th17 cells (Figure 4a and b).
Soluble TGF-b1, BAFF and APRIL were readily
detectable in patients’ blood and were
significantly higher in adult patients than in
controls (Figure 4c). Hence, the defect in IgA class
switching in our sIgAD patients does not seem to
be related to decreased blood concentrations of
these cytokines.
DISCUSSION
In the present study, we searched for underlying
B-cell intrinsic and extrinsic defects in children and
adults with sIgAD by characterising the peripheral
blood B-cell and T-cell compartments, IGA
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transcripts and cytokine concentrations. We
observed a reduction in TI-derived CD27IgA+ and
TD-derived CD27+IgA+ memory B cells in all
patients. We did not find an in vivo class switch
defect to downstream IGG and IGA subclasses,
and affinity maturation of IGA transcripts of
sIgAD patients was similar to controls. However,
patients had reduced Th1 and Th17 cells and
increased blood concentrations of TGF-b1, BAFF
and APRIL. Together, these results indicate that
sIgAD patients have defective regulation of the
IgA response.
Nine out of 12 children and 17 out of 18 adults
from our cohort with sIgAD suffered from
recurrent infections, and several exhibited atopy
and autoimmunity. However, the four
asymptomatic patients did not differ
immunologically from symptomatic patients.
Therefore, symptomatic patients will benefit from
a better understanding of the pathophysiology of
sIgAD that lead to new treatment strategies.
Recently, Blanco et al.15 showed that the
detection of IgA+ memory is not related to the
presence of symptoms in sIgAD patients. The
majority of adult patients in our cohort had
undetectable peripheral IgA+ memory B cells,
which is higher than in the study of Blanco et al.,
in which IgA+ memory B cells were undetectable
in 50% of the patients. The authors defined two
IgAD groups: individuals in group 1 had a normal
to a mild decrease in number of IgA+ memory B
cells. In contrast, in group 2, individuals had
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severe deficiency or undetectable IgA+ memory B
cells. The percentages of symptomatic patients did
not differ between the two groups. However,
sIgAD patients from group 2 experienced more
frequently respiratory tract infections and
autoimmunity.15 Therefore, adult patients in our
study may be more comparable to the sIgAD
patients of group 2 than group 1.
The generation of IgA2+ memory B cells is
mainly TI at mucosal sites such as the lamina
propria in the intestine.6 Our results showing a
deficiency of TI- and TD-derived IgA+ memory B
cells in our patients are in line with the presence
of both IgA1+ and IgA2+ memory B cells in sIgAD
patients.15
Although by definition, patients with sIgAD
have normal IgG, some authors suggest that this
disease may be part of a clinical spectrum of
disorders such as CVID, based on the observation
that some individuals initially diagnosed with
sIgAD, progressed over time.31-34 Furthermore,
genetic variants in TNFRSF13B are more prevalent
in both disorders and can coexist within the same
family.16 However, our two patients in which we
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found two previously reported TNFRSF13B variants
associated with CVID did not show additional
abnormalities in the B-cell compartment typical
for CVID, such as decreased IgM+ or IgG+ memory
B cells.
Interestingly, the SHM levels and degree of
antigenic selection we identified were
characteristics of normal affinity maturation of
IGA and IGG in sIgAD patients. In contrast, CVID
patients frequently show an abnormal antigen-
selected Ig gene repertoire with reduced SHM
levels in IGA and IGG and abnormalities in
subclass distribution such as decreased IGG2
usage.35,36 Our findings of increased IGA2 usage
in children with sIgAD and normal downstream
usage of IGG subclasses in adults make a class
switch defect in sIgAD patients in our cohort
unlikely. It remains unclear why IGA2 transcripts
were enriched in children with sIgAD, as this is a
relative measure and could result from the overall
reduction and a more severe reduction in IGA1.
Importantly, patients were able to switch to both
IgA subclasses in vivo, excluding an entire block in
Ig switching to one or both IGA regions.
Previously, in vitro studies had focused on the
production of IgA, differentiation into
plasmablasts or upregulation of AID.29 Our short-
term in vitro stimulations showed that TD and TI
stimuli did not differ in terms of B-cell activation.
Patients with predominantly antibody
deficiency, including CVID, have reduced numbers
of Th17 cells along with increased numbers of
CD21low B cells.36-38 Interestingly, we found
decreased Th17 and Th1 cell numbers in adult
sIgAD patients. Recently, Lemarquis et al.14
studied fifteen IgAD patients and did not find
abnormalities in Th1 and Th17 cells. These
contradictory findings could result because they
used the proportion of T helper cells as a fraction
of CD4+ T cells. Patients with congenital
agammaglobulinemia, who lack mature B cells,
exhibit decreased frequencies of Th17 cells.37
However, these authors questioned the role of B
cells in the differentiation of Th17 cells as they
showed that in healthy individuals, there is a
negative correlation between frequencies of Th17
cells and class-switched memory B cells and serum
concentrations of BAFF.37 We observed elevated
concentrations of BAFF and APRIL in our adult
SIgAD patients. This has also been described for
children with sIgAD.39 Since total B-cell numbers
were normal in our adult patients, it remains
unclear whether the increase in blood BAFF and
APRIL levels results from increased production or
decreased usage by target cells. In future studies,
it would be essential to study dendritic cells as
well as T helper cells and cytokine concentrations
at local mucosal sites where IgA class switching
occurs. Also, it would be interesting to elucidate
whether Th17 and Th1 cells are also low in sIgAD
patients who have detectable IgA+ memory B
cells, as well as comparisons of T helper cell
numbers between sIgAD patient groups 1 and 2,
as recently defined.15 These studies might provide
further insights into the role of Th17 cells in
sIgAD.
Another essential cytokine in the regulation of
IgA class switching is TGF-b1. More than two
decades ago, Muller et al.,40 using a cell bioassay,
noted a moderate reduction in serum
concentrations of TGF-b1 in sIgAD patients, and
these correlated negatively with the numbers of
CD19+ B cells.38 In contrast, we found increased TGF-
b1 in plasma in five out of 8 patients. Moreover,
nearly all patients from our cohort exhibited normal
numbers of B cells in peripheral blood. In mice, the
lack of TGF-b receptor expression on B cells leads to
defective IgA production.41 Therefore, it will be
interesting to measure TGF-b receptor expression,
since a significant decrease might explain the high
levels of this cytokine observed in some of our
patients. Searching for possible genetic defects
affecting the signalling cascade of costimulatory
molecules beyond TNFRSF13B or costimulatory T-
helper cells might provide additional insights into
the pathogenesis of sIgAD.
In summary, we show here that in addition to
the absence of IgA in blood, symptomatic sIgAD
patients are defective in the formation of IgA
memory B cells, despite normal B-cell activation
and affinity maturation of their IGA and IGG
transcripts. Instead, decreased Th1 and Th17 cell
numbers and high levels of BAFF, APRIL and TGF-
b1 might reflect disturbed regulation of IgA
responses in vivo. We propose that the severe
impairment in IgA class switch in symptomatic
sIgAD patients might result from shifts in Th cell
subsets and cytokine dysregulation.
METHODS
Human subjects
We collected clinical data and blood samples of 30 patients
(children n = 12; adults n = 18) with sIgAD and 108 healthy
controls (children n = 72; adults n = 29) after written
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informed consent (Supplementary table 1). All patients
were diagnosed based on the absence of serum IgA
(< 0.07 g L1) with normal IgM and IgG. This study was
performed according to the Declaration of Helsinki and the
guidelines of the Medical Ethics Committees of the Erasmus
MC, Karolinska University Hospital, and ethics committee at
the University of Antioquia.
Flow cytometry and cell sorting
Absolute counts of blood CD3+ T cells, CD16+/56+ natural
killer cells and CD19+ B cells were obtained with a
diagnostic lyse-no-wash protocol (BD Biosciences, San Jose,
CA, USA). Detailed immunophenotyping of B and T cells
was performed by 11-colour flow cytometry using an LSRII
Fortessa (BD Biosciences) with a standardised configuration,
according to Euroflow protocols.42 Data were analysed
using FacsDIVA software v8 (BD Biosciences) and Infinicyt
software (Cytognos, Salamanca, Spain). Control subjects
were described previously.26,27 All antibodies used for flow
cytometry are listed in Supplementary table 2. The gating
strategy of B-cell subsets is shown in Supplementary figure 1.
T-cell subsets were defined as follows: naive T cells (CD45RO
CCR7+), central memory (CM) T cells (CD45RO+CCR7+),
effector memory (EM) T cells (CD45RO+/CCR7), Th1
(CD45RACCR6CXCR3+CCR4), Th2 (CD45RACCR6CXCR3
CCR4+), Th17 (CD45RACCR6+CXCR3CCR4+), regulatory T
cells (Treg; CD25+CD127) and follicular helper T cells (Tfh;
CD45RO+CXCR5+).27,43 Naive mature B cells (CD3CD20+
CD38lowCD27IgD+) were high-speed cell sorted to > 95%
purity using a FACSAria III (BD Biosciences).
In vitro B-cell activation and cell cultures
Purified naive mature B cells were cultured at a density of
30 000 cells/200 lL per well in round-bottom 96-well plates
with RPMI medium (Lonza, Basel, Switzerland) containing
10% foetal calf serum (Thermo Fisher Scientific, Waltham,
MA, USA), 1% penicillin/ampicillin and 0.5 lM 2-
mercaptoethanol (Thermo Fisher Scientific). Cells were
stimulated for 48 h with either 10 lg mL1 of anti-CD40
(Bioceros B.V., Utrecht, the Netherlands), 10 lg mL1 F(ab0)2
anti-IgM (Southern Biotech, Birmingham, AL, USA), 0.5 lM
CpG ODN2006 (Invivogen, San Diego, CA, USA) or
1 µg mL1 APRIL (AdipoGen Life Sciences, San Diego, CA,
USA) in combination with 0.5 ng mL1 TGF-b (R&D Systems,
Minneapolis, MN, USA) and harvested to determine the
expression levels of surface activation marker by flow
cytometry (Supplementary table 2).
Molecular analysis of somatic
hypermutations and Ig subclass usage
RNA was isolated from PBMCs with the GeneElute
Mammalian Total RNA Miniprep kit (Sigma-Aldrich, St.
Louis, MO, USA), followed by cDNA synthesis. IGA and IGG
transcripts were amplified using IGHV3 and IGHV4 leader or
FR1 primers in combination with a Ca or Cc reverse
primer.8,44 PCR products were cloned into the pGEM-T easy
vector (Promega, Leiden, the Netherlands) and prepared for
sequencing on an ABI PRISM 3130XL (Applied Biosystems,
Foster City, CA, USA). The sequences obtained were
compared with reference sequences from the IMGT
database (http://imgt.org). Targeting of SHM in framework
regions (FR) and complementarity determining regions
(CDR) was analysed with the extended version of IGGalaxy
(http://bioinf-galaxian.erasmusmc.nl/galaxy).45 The selection
strength for replacement mutations in the FR and CDR was
determined with the Bayesian estimation of Antigen-driven
SELectIoN program (http://selection.med.yale.edu/baseline/)46,47
IgG and IgA subclasses were determined using the germline
sequence of IGH locus (NG_001019).
TNFRSF13B mutation analysis
Five exons of the TNFRSF13B gene encoding TACI were
amplified by PCR (primers listed in Supplementary table 3)
and sequenced on an ABI PRISM 3130XL (Applied
Biosystems).
Anti-IgA antibody analysis
Plasma antibodies directed against IgA (anti-IgA) were
analysed at Sanquin laboratories (Amsterdam, the
Netherlands), using the commercially available EliATM Anti-
IgA enzyme immune assay (Phadia, Thermo Fisher Scientific,
Uppsala, Sweden). The assay was performed on the
Phadia250 analyser according to the manufacturer’s
instructions without modification. Reference values used in
this assay were < 3 U mL1 negative; 3–10 U mL1
borderline; > 10 U mL1 positive.
Quantification of BAFF, APRIL and TGF-b1
An ELISA was used to measure BAFF, APRIL and TGF-b1
concentrations in plasma and serum samples of sIgAD
patients (adults n = 14; children n = 12) and controls (only
adults n = 24), according to the manufacturer’s instructions
(BAFF and TGF-b1 R&D systems; APRIL, eBioscience, San
Diego, CA, USA).
Statistics
Statistical analyses were performed with the Mann–Whitney
U-test or chi-square test, as indicated in the figure legends.
P-values of < 0.05 were considered to be statistically
significant as follows: * < 0.05, ** < 0.01, *** < 0.001, ****
< 0.0001.
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